Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurementPsychedelics · 2026-12-01Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelPsychedelics · 2026-12-01Psilocybin for anorexia nervosa: efficacy, safety, and durability of clinical effects: a systematic review of clinical trialsDebates em Psiquiatria · 2026-11-09Current perspectives in the pharmacological treatment of gambling disorder: psychedelics and beyond.Expert opinion on pharmacotherapy · 2026-11-09Psilocybin Recovery Intervention for Stopping Methamphetamine UseClinicalTrials.gov · 2026-11-09Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-11-09Rapid antidepressant effects of psilocybin without increased SV2A binding: baseline binding predicts responsemedRxiv · 2026-11-08Psilocybin-assisted therapy for alcohol use disorder: A systematic review of randomized controlled trialsPharmacotherapy in Psychiatry and Neurology · 2026-11-06Pharmacist Guide to Psilocybin and Psychedelic-Assisted Psychotherapy.American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists · 2026-11-06Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive DisorderClinicalTrials.gov · 2026-11-06Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)ClinicalTrials.gov · 2026-11-06A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?ClinicalTrials.gov · 2026-11-06Psilocybin for Amblyopia - Targeting Critical Periods in Humans (PATCH)ClinicalTrials.gov · 2026-11-05A Topology of the Psilocybin Experience Reveals Cognitive-Emotional Drivers, Unitive State Divergence, and Psychometric Feature CancellationPsyArXiv · 2026-11-05Which Psychedelic Therapy Should Rural Health Systems Pursue First: Psilocybin or Ibogaine?The Permanente Journal · 2026-11-05Psilocybin modulates nucleus accumbens activity via astrocytic transcriptional regulation.Experimental & molecular medicine · 2026-11-05A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)ClinicalTrials.gov · 2026-11-05Pilot Study of Psilocybin-assisted Treatment for Cannabis Use DisorderClinicalTrials.gov · 2026-11-05Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-11-05Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderClinicalTrials.gov · 2026-11-05A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2026-11-05Scn2a -deficient mice exhibit serotonergic dysfunction and altered behavioral responses to psilocybinbioRxiv · 2026-11-04A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back PainClinicalTrials.gov · 2026-11-04The Bicuspid Aortic Valve Within the Therapeutic Window of Cannabis, Tryptamines, and Novel Neuroplastogen Analogs: A Mechanistic Risk Analysis Anchored to a Reconstructed openSNP Genotype CohortPreprints.org · 2026-11-03Estimations of the Vaporization Enthalpies of a Series of Licit and Illicit Drugs by Synthetic Analysis and Group AdditivityResearch Square · 2026-11-03Psilocybin-Assisted Therapy for Cancer-Related Psychological and Existential Distress in Adults with Cancer: An Integrative Systematic Review.Journal of pain & palliative care pharmacotherapy · 2026-11-03TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-11-03TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-11-03NeuroGuard: Psilocybin Trial for Preventing Chemo-induced NeuropathyClinicalTrials.gov · 2026-11-03From Evidence to Practice: A Systematic Review of Implementation of Psychedelic-Assisted Psychotherapy.Psychedelic medicine (New Rochelle, N.Y.) · 2026-11-02Psilocybin FCR Early-Stage Breast CancerClinicalTrials.gov · 2026-11-02PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-11-02A multi-institutional investigation of psilocybin's effects on mouse behavior.Nature neuroscience · 2026-11-02Furthering the Understanding of Psilocybin Use and Molecules Relevant to Depression and Schizophrenia.The American journal of psychiatry · 2026-11-01Psilocybin Use in Psychiatry: Clinical Practice and Public Health Implications.The American journal of psychiatry · 2026-11-01How Psilocybin Alters Consciousness: Psychedelics can create a "hidden order" in brain activity that could explain how these drugs affect our sense of self.Scientific American · 2026-11-01Serotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH.Clinical drug investigation · 2026-11-01Prior trauma shapes the effects of psilocybin on stress sensitization in miceNeuroscience Letters · 2026-11-01Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine: A systematic review of clinical and preclinical evidence.Neuroscience and biobehavioral reviews · 2026-11-01Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.CNS drugs · 2026-11-01Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary AnalysisJournal of Pain and Symptom Management · 2026-11-01Pupil-DLC: An open-source deep learning pipeline for scalable, marker-less tracking of pupil dynamics across conscious and unconscious states.Journal of neuroscience methods · 2026-11-01α-Adrenergic receptor modulates 5-HT-mediated behavioral effects of MDMA and psilocybin in mice.Molecular psychiatry · 2026-11-01Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.The International journal of eating disorders · 2026-11-01Safety and efficacy of psilocybin-assisted therapy for alcohol use disorder: Open-label extension of a phase II randomized controlled trialDrug and Alcohol Dependence · 2026-11-01Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant DepressionValue in Health Regional Issues · 2026-11-01Prevalence and Correlates of Past-Year Psilocybin Use in the United StatesAmerican Journal of Psychiatry · 2026-11-01Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-11-01Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.Molecular psychiatry · 2026-11-01Psychedelics restructure information in the human brainbioRxiv · 2026-10-31Structural plasticity and enhanced fear extinction following psilocybin in chronically stressed micebioRxiv · 2026-10-31Psilocybin as a novel drug in the treatment of major depressive disorder: a systematic reviewMedical Science · 2026-10-30The 'Civilising' of Psychedelics: Pharmaceuticalisation from Below as a Part-Process of American and European InformalisationHuman Figurations · 2026-10-30The role of music therapy in psychedelic treatment: The case for safe, supported soundJournal of Psychedelic Studies · 2026-10-30The Fireside Database: Large-scale evidence from 25,419 psychedelic support interactions.Science advances · 2026-10-30Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesClinicalTrials.gov · 2026-10-30Consciousness and Psilocybin Effects on Well-Being: The CoPEWell StudyClinicalTrials.gov · 2026-10-30Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.Journal of affective disorders · 2026-10-30Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-10-30Psychedelics and Psychedelic-Inspired Compounds for Substance Use Disorders: Are We Treating the Disease or Opening a Learning Window?Brain Sciences · 2026-10-29Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trialmedRxiv · 2026-10-29Multi-scale effects of single-dose psilocybin in the macaque brainResearch Square · 2026-10-29A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.ClinicalTrials.gov · 2026-10-29A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-10-29An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality DisorderClinicalTrials.gov · 2026-10-29Quantum Chemical Topology and Energetic Analysis of Psychedelic and Non-Psychedelic Ligands in Coordination-Sphere Models of the Human 5-HT2A ReceptorResearch Square · 2026-10-28Connectedness as a candidate pathway linking psilocybin retreat experiences to sustained wellbeing: a prospective naturalistic studyFrontiers in Psychiatry · 2026-10-28High-Quality Genome Assembly and Transcriptomic Analysis Reveal Potential Pathways for Psilocybin Biosynthesis in Gymnopilus dilepisJournal of Fungi · 2026-10-28Psychedelic assisted psychotherapy (2020-2025): a scoping review of clinical evidence, mechanisms, safety, and ethicsFrontiers in Psychology · 2026-10-27Psychedelics and psychosis: A systematic review of recent-era studies (1984-2025).Journal of psychopharmacology (Oxford, England) · 2026-10-27Magic pathways: the genes and enzymes of psilocybin biosynthesis.Microbiology and molecular biology reviews: MMBR · 2026-10-27Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-10-27Safety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among VeteransClinicalTrials.gov · 2026-10-26Substantial Treatment-Seeking Interest, Narrow Eligibility: Diagnostic Heterogeneity and External Validity in the PRIDE Psilocybin Trial-Relevance to Precision PsychiatryBehavioral Sciences · 2026-10-26Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.JAMA · 2026-10-26Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis.Psychopharmacology · 2026-10-26Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-10-26Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-10-26Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy OutcomesClinicalTrials.gov · 2026-10-26Direct Quantitation of Psilocybin and Psilocin by 1H and 31P qNMR in Wild Psilocybe from GreeceACS omega · 2026-10-24Preparing the body for psilocybin therapy: receptive and generative interoception in cancer patientsFrontiers in psychiatry · 2026-10-24Psilocybin and Clinical DepressionResearchGate · 2026-10-23Sustained antidepressant-like effects of psychedelics through 5-HT2AR-β-arrestin signaling.Nature neuroscience · 2026-10-23Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use DisorderClinicalTrials.gov · 2026-10-23A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-10-23Mikrodosiertes Psilocybin im palliativmedizinischen KontextSchmerz Nachrichten · 2026-10-21Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease: A Nonrandomized Clinical Trial.JAMA psychiatry · 2026-10-21A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-10-21Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical TrialClinicalTrials.gov · 2026-10-21Clinical Evidence on Psilocybin and Its Representation in Media ReportingJAMA Network Open · 2026-10-20Direct Quantitation of Psilocybin and Psilocin by H and P qNMR in Wild from Greece.ACS omega · 2026-10-20A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-10-20Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinClinicalTrials.gov · 2026-10-20Microdosing Psychedelics to Improve MoodClinicalTrials.gov · 2026-10-20Psilocybin for anhedonia in unipolar and bipolar depression: A systematic review of clinical and preclinical evidence.Journal of psychiatric research · 2026-10-19Michael Pollan’s Psychedelic Renaissance: Settler Colonial Time and the De-Indigenization of Mazatec Mushroom MedicineA Contracorriente: una revista de estudios latinoamericanos · 2026-10-19Biosynthesis of gold nanoparticles using Psilocybe cubensis extracts and their biostimulatory evaluation in Neuro2a cellsFrontiers in Nanotechnology · 2026-10-19Psilocybin in Treatment-Resistant Depression: Weighing Rapid Antidepressant Effects Against Uncertain DurabilityTherapeutics · 2026-10-19Investigation of the pharmacological and circuit basis for psychedelic drug effects on interval timing in mice.Psychopharmacology · 2026-10-19Psychoplastogens to Reduce Persistent Cognitive Symptoms for Traumatic Brain Injury as a Chronic Condition.Journal of neurotrauma · 2026-10-19Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-10-19A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-10-19From Altered States to Fundamental Peace: Taxonomies of Consciousness, Psychedelics and Hypnosis Through the Lens of the Yoga VāsiṣṭhaOpenAlex · 2026-10-18Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice.Psychopharmacology · 2026-10-17Adverse outcomes of psychedelics self-reported: SurveyAlcoholism & Drug Abuse Weekly · 2026-10-16French psychiatric caregivers' perceptions of psychedelics: A national survey.L'Encephale · 2026-10-16The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of PsilocybinClinicalTrials.gov · 2026-10-16Context Shapes Alpha-Band Electrophysiological Signatures Under PsilocybinbioRxiv · 2026-10-16Coding and Classification Errors in Study of Psilocybin ServicesJAMA Network Open · 2026-10-16Stroboscopic light stimulation as a controllable probe of the psilocybin state: a mechanistic framework and a falsifiable predictionFrontiers in pharmacology · 2026-10-16Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept TrialClinicalTrials.gov · 2026-10-16Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.ClinicalTrials.gov · 2026-10-16Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot StudyClinicalTrials.gov · 2026-10-16Aspirational Autonomy and Psychedelic-Assisted Therapy in Advanced Cancer: Ethical Lessons from Clinical Cases.The oncologist · 2026-10-155-HT2A receptors in layer 5 pyramidal neurons mediate the neuroplastic but not the hallucinogenic effects of psilocybin.Nature neuroscience · 2026-10-15Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled TrialClinicalTrials.gov · 2026-10-15Connectedness as a mechanism of change in psilocybin-assisted cognitive behavioral therapy for major depressive disorderPsychedelics · 2026-10-14Mechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways.CNS & neurological disorders drug targets · 2026-10-14The Hidden Therapeutic Bridge: Exploring Psilocybin's Role in Depression, Inflammation, and Pain - A Narrative Review.Current neuropharmacology · 2026-10-14Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy NetworkFrontiers in Psychiatry · 2026-10-14AI-assisted characterization of psychedelic clinical trials from ClinicalTrials.govTrials · 2026-10-14Group psilocybin in an integrative retreat setting enhances social connection: an observational case reportPsyArXiv · 2026-10-14Language-associated brain representations covary with disruption of selfhood under psilocybinbioRxiv · 2026-10-14A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced CancerClinicalTrials.gov · 2026-10-14Psilocybin-based interventions for depressive symptoms: robustness and variation across meta-analytic specificationsResearchGate · 2026-10-13Acute anxiogenic effects of psilocybin and the related tryptamine, norbaeocystin, in male and female rats.Psychopharmacology · 2026-10-13Cannabis and Psilocybin Co-use: Associations with Stress and Well-beingInternational Journal of Mental Health and Addiction · 2026-10-13Psilocybin enhances conditioned place preference learning in planarians.Behavioural pharmacology · 2026-10-13Quality of Life and the Case for Consent-Based Psilocybin Access - Questions on the Regulatory Framework and CostPsyArXiv · 2026-10-13An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-10-13Investigating molecular and hemodynamic effects of LSD in the human brain.Nature neuroscience · 2026-10-12Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant responseNeuropsychopharmacology · 2026-10-12Mystical experiences mediate the effects of psilocybin-assisted psychotherapy + mindfulness-based stress reduction on trait mindfulness and depression symptoms: mechanistic results from a randomized controlled trialJournal of Affective Disorders Reports · 2026-10-11Psilocybin-Assisted Therapy for Existential Distress in Serious and Life-Limiting Illness: Emerging Trial Evidence, Barriers to Access, and the Case for Individualized EligibilityPsyArXiv · 2026-10-11Psychedelics and Sleep: Preclinical and Human Studies-A Systematic ReviewPsychiatry and Clinical Psychopharmacology · 2026-10-10Psychedelics in neurosurgery: Potential utility in prevention, perioperative care, pain management, and neurorehabilitationSurgical Neurology International · 2026-10-09Molecular Mechanism of Psilocybin-Induced Longevity: The c-Fos-SIRT6 Epigenetic AxisResearch Square · 2026-10-09Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb PainClinicalTrials.gov · 2026-10-09Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-10-09Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysisJournal of Psychopharmacology · 2026-10-08Pilot Study on the Effects of Psilocybin on Belief Updating and Insight FormationClinicalTrials.gov · 2026-10-08Music for psilocybin therapy and the temporal arc of psychedelic experienceScientific Reports · 2026-10-08Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male miceFrontiers in pharmacology · 2026-10-07What Is Psilocybin?JAMA · 2026-10-06Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialClinicalTrials.gov · 2026-10-06PsilocybinJAMA · 2026-10-06Psilocybin-Assisted Therapy in Depressive Disorders: Clinical Governance, Safety, and Translational ChallengesResearchGate · 2026-10-05Caution before canonisation: a clinical and implementation science perspective on psychedelicsFrontiers in Psychiatry · 2026-10-05Psychedelics Restructure the Global Workspace of ConsciousnessbioRxiv · 2026-10-05Therapists’ Perspectives on the Psychotherapeutic Support in Psilocybin Treatment for Major Depressive Disorder: Insights from a Randomized Controlled TrialResearch Square · 2026-10-05An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder.medRxiv · 2026-10-05Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive ImpairmentClinicalTrials.gov · 2026-10-05Study participant perceptions of the relevance of therapist and study team personal psychedelic experiencePsychedelics · 2026-10-03Psychedelics and disorders of consciousness: a new frontier in neurotherapeutics.Molecular psychiatry · 2026-10-03Through the PRISM: Reinterpreting Psychedelic Cognition as Motivational ReallocationPsyArXiv · 2026-10-02From regulation to practice: A scoping review of prescribers’ roles in psilocybin-assisted therapyDrug Science, Policy and Law · 2026-10-01Placebo, Psilocybin und der vermaledeite p-WertNervenheilkunde · 2026-10-01Open-label, Single-arm fMRI Study Evaluating the Effects of Psilocybin on Craving in Nicotine Dependence.ClinicalTrials.gov · 2026-10-01Embeddedness under psilocybin.Nature neuroscience · 2026-10-01The New Mexico Medical Psilocybin Act and current trends in the United States psychedelic policyPsychedelics · 2026-10-01F25. COMPARING PSILOCYBIN-ASSISTED THERAPY AND SSRIS IN THE TREATMENT OF LATE-LIFE DEPRESSIONThe American Journal of Geriatric Psychiatry · 2026-10-01MedCheck: Drugmakers Advance Psilocybin, Oral Pregnanolone for MDD, Plus FDA Approves Pediatric Tourette's Drug, and MorePsychiatric News · 2026-10-01Psilocybin restores spatial memory but not fronto-hippocampal synchrony in a rat model of Alzheimer's diseaseNeuroscience Research · 2026-10-01Oregon’s State-Regulated Psilocybin Services: Early Real-World Safety SignalsPsyArXiv · 2026-10-01Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis.CNS drugs · 2026-10-01Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics.The International journal on drug policy · 2026-10-01Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations.British journal of clinical pharmacology · 2026-10-01Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-10-01Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges.Journal of psychiatric research · 2026-10-01The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSDClinicalTrials.gov · 2026-10-01Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in ratsPharmacology Biochemistry and Behavior · 2026-10-01Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use.Community mental health journal · 2026-10-01Large-Scale and Local Functional Connectivity Changes following Psilocybin Administration in Methamphetamine Use Disorder.AJNR. American journal of neuroradiology · 2026-10-01Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats.Neuroscience bulletin · 2026-10-01Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.Molecular psychiatry · 2026-10-01Worsening of Depression and Anxiety With Psilocybin: A Case Report in Cyclothymia.The Journal of clinical psychiatry · 2026-09-30Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative reviewFrontiers in psychiatry · 2026-09-30U.S. Veterans and Psychedelics: Prevalence of Use and Policy Preferences.Rand health quarterly · 2026-09-29Reduced egocentricity after psilocybin in patients with alcohol use disorder: a pilot randomized controlled trialmedRxiv · 2026-09-29Psilocybin in psychiatry: Current clinical evidence, mechanisms of action and translational perspectives. A literature review based on PubMed-indexed studiesPharmacotherapy in Psychiatry and Neurology · 2026-09-29Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMTJAMA Network Open · 2026-09-29Targeting the serotonin 1B receptor for the treatment of depression and anxiety.Expert opinion on therapeutic targets · 2026-09-28The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-09-28Psilocybin for Treatment-Resistant Major Depression: Efficacy, Safety and Therapeutic MechanismsHeidelberg University repository (HeiDOK) · 2026-09-24Age moderates the relationship between psychedelic use and mental health in naturalistic settingsScientific Reports · 2026-09-24Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-09-24Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-09-24Psilocybin and Contrasting Musical Compositions: Effects on Music-Evoked Emotional Responses in Healthy AdultsmedRxiv · 2026-09-23Preclinical Anxiolytic- and Antidepressant-like Effects of α,α-Trehalose, a Bioactive Compound Identified in Psilocybe cubensisMolecules · 2026-09-23Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility StudyClinicalTrials.gov · 2026-09-23Apomorphine and psilocybin to improve recovery from coma in the intensive care unit: protocol for a prospective, open-label, dose-escalation study.BMJ open · 2026-09-22Reply to 'Methodological concerns and interpretative limitations of assessing subjective effects of ketamine'.Npj mental health research · 2026-09-22ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-09-22Curious about Psilocybin? Prevalence and correlates of interest among adults with chronic pain.Authorea Preprints · 2026-09-21EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEWInternational Journal of Innovative Technologies in Social Science · 2026-09-21A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy AdultsPharmaceuticals · 2026-09-21Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.British journal of clinical pharmacology · 2026-09-21An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.The Journal of clinical psychiatry · 2026-09-21A Case of Acute Mania and Rhabdomyolysis Associated With Long-Term, Daily Psilocybin Use.Journal of clinical psychopharmacology · 2026-09-21